

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2026*

POTENTIAL APPROVALS US/EU

✓ US TREMFYA (guselkumab)
Psoriatic Arthritis Structural
Damage (APEX)

✓ US ICOTYDE (icotrokinra)
EU Psoriasis (ICONIC)

US nipocalimab
Warm Autoimmune Hemolytic
Anemia (ENERGY)

AKEEGA (niraparib/abiraterone)
EU M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)

✓ US DARZALEX (daratumumab)
Frontline multiple myeloma
transplant ineligible (CEPHEUS)

✓ US TECVAYLI (teclistamab)
EU Multiple Myeloma 1-3PLs
(MajesTEC-3)

TECVAYLI (teclistamab)
EU Relapsed Refractory Multiple
Myeloma CD38 exposed
(MajesTEC-9)

PLANNED SUBMISSIONS US/EU

✓ US nipocalimab
Warm Autoimmune Hemolytic
Anemia (ENERGY)

US CAPLYTA (lumateperone)
Bipolar Mania

US ERLEADA (apalutamide)
EU Localized Prostate Cancer (ATLAS)

US ERLEADA (apalutamide)
EU High Risk Prostate Cancer (PROTEUS)

US bleximenib
Relapsed Refractory Acute Myeloid
Leukemia (cAMeLot-1)

✓ US TALVEY (talquetamab)
✓ EU Relapsed Refractory Multiple Myeloma
A-CD38 Naïve (MonumenTAL-3)

US TALVEY (talquetamab)
EU Relapsed Refractory Multiple Myeloma
CD38 exposed (MonumenTAL-6)

✓ US TECVAYLI (teclistamab)
✓ EU Relapsed Refractory Multiple Myeloma
CD38 exposed (MajesTEC-9)

TECVAYLI (teclistamab)
✓ EU Multiple Myeloma 1-3PLs (MajesTEC-3)

✓ US RYBREVANT (amivantamab)
Head and Neck Cancer (ORIGAMI-4)

INLEXZO (gemcitabine intravesical
delivery system)
US High Risk Non Muscle Invasive Bladder
EU Cancer BCG Experienced (SunRISe-5)

POTENTIAL CLINICAL DATA PRESENTATIONS¹

Phase III

✓ ICOTYDE (icotrokinra)
Psoriasis (ICONIC-ADVANCE
1&2 Update)

ICOTYDE (icotrokinra)
Psoriasis (ICONIC-ASCEND)

icotrokinra
Psoriatic Arthritis (ICONIC-
PsA)

ICOTYDE (icotrokinra)
Psoriasis (ICONIC-TOTAL
Update)

CAPLYTA (lumateperone)
Bipolar Mania (ITI-007-452)

✓ nipocalimab
Warm Autoimmune Hemolytic
Anemia (ENERGY)

ERLEADA (apalutamide)
Localized Prostate Cancer (ATLAS)

✓ ERLEADA (apalutamide)
High Risk Prostate Cancer (PROTEUS)

✓ TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma
A-CD38 Naïve (MonumenTAL-3)

TALVEY (talquetamab)
Relapsed Refractory Multiple Myeloma
CD38 exposed (MonumenTAL-6)

✓ TECVAYLI (teclistamab)
Relapsed Refractory Multiple Myeloma
CD38 exposed (MajesTEC-9)

INLEXZO (gemcitabine intravesical
delivery system)
High Risk Non Muscle Invasive Bladder
Cancer BCG Experienced (SunRISe-5)

Phase I/ II

✓ JNJ-4804 Co-antibody Therapy
Ulcerative Colitis (DUET-UC)

✓ JNJ-4804 Co-antibody Therapy
Crohn's Disease (DUET-CD)

✓ JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis (AFFINITY)

✓ nipocalimab
Systemic Lupus Erythematosus
(JASMINE)

bleximenib
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)

pasritamig + JNJ-9401
Prostate Cancer (PCR1001)

JNJ-6143 (HLD-0915)
Prostate Cancer (FIH Update)

✓ = Achieved

1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of July 15, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.